European drugmakers say they are ‘losing ground’ to US and Chinese rivals

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-22T15:10:55.034Z • Permanent link

European pharmaceutical companies are sounding the alarm, warning that the continent is "losing ground" to US and Chinese rivals in the highly competitive global market. The call to action comes from some of Europe's biggest pharma firms, including GlaxoSmithKline, Pfizer, and Novartis, who have written to national leaders calling for urgent reforms to safeguard their futures. The letter, penned by the CEOs of these companies, has sparked a heated debate about the need for greater investment in research and development, as well as more effective regulatory frameworks.

The CEOs' letter highlights the stark reality of Europe's pharma sector, which has been facing increasing pressure from low-cost generics and biologics from the US and China. According to data from the European Pharmaceutical Industry Employee Committee, the EU's pharma industry is expected to lose an estimated €30 billion in sales by 2025, with many companies struggling to compete with the likes of Biogen and Pfizer's Aduhelm. The CEOs' letter specifically points to the need for greater investment in research and development, as well as more effective patent protection and regulatory frameworks to safeguard their intellectual property.

The CEOs' letter also raises questions about the role of the European Commission and EU regulators in supporting the pharma industry. The letter calls for greater support for research and development, as well as more effective regulation of the generic and biosimilar markets. The CEOs also express concerns about the impact of Brexit on the pharma industry, with many companies struggling to navigate the new regulatory landscape.

The crisis facing Europe's pharma industry has far-reaching implications for the global economy and public health. The EU's pharma industry is a significant contributor to the region's GDP, with many companies playing a critical role in developing and manufacturing life-saving medicines. The loss of these companies could have a devastating impact on the European economy, with many jobs and industries at risk. Furthermore, the crisis also has significant implications for public health, with many countries relying on European pharma companies to develop and manufacture medicines.

The crisis also has significant implications for research communities and academic institutions. The EU's pharma industry is a major driver of research and development, with many companies investing heavily in basic research and translational research. The loss of these companies could have a significant impact on the development of new medicines, with many researchers and academics struggling to find alternative funding sources. The crisis also raises questions about the role of academia in supporting the pharma industry, with many researchers and academics struggling to navigate the complex regulatory landscape.

The crisis facing Europe's pharma industry is part of a broader pattern of decline in the sector, which has been facing increasing pressure from low-cost generics and biologics from the US and China. The rise of low-cost generics and biologics has been driven by a combination of factors, including advances in manufacturing technology and the increasing availability of data on drug development. The US and China have been at the forefront of this trend, with companies such as Pfizer and Biogen developing and manufacturing low-cost generics and biologics that are competing with established pharma companies.